Business context and reporting period
The filing is Prestige Brands Holdings, Inc.’s Form 10-K for the fiscal year ended March 31, 2014—not a standalone “2013 Q4” report. The company markets OTC healthcare and household-cleaning products, primarily in North America. The filing’s registrant name differs from the requested company name, Prestige Consumer Healthcare Inc.
OTC Healthcare generated 85.4% of fiscal 2014 revenue; Household Cleaning generated 14.6%. The company acquired Care Pharmaceuticals in July 2013, expanding into Australia and New Zealand.
Financial results and liquidity
| Metric | FY2014 | FY2013 |
|---|---|---|
| Total revenue | $601.9 million | $623.6 million |
| Gross profit / margin | $340.1 million / 56.5% | $347.2 million / 55.7% |
| Operating income / margin | $188.6 million / 31.3% | $191.9 million / 30.8% |
| Net income | $72.6 million | $65.5 million |
| Diluted EPS | $1.39 | $1.27 |
| Cash from operating activities | $111.6 million | $137.6 million |
| Capital expenditures | $2.8 million | $10.3 million |
| Cash and cash equivalents at year-end | $28.3 million | $15.7 million |
| Total debt, including current maturities | $937.5 million | $978.0 million |
Net income rose despite lower revenue and operating income, reflecting lower net interest expense and a lower effective tax rate; an $18.3 million debt-extinguishment loss partly offset those benefits. The tax rate was 28.6%, versus 38.2%, including an $8.9 million noncash benefit from lower expected state taxes.
Cash from operations fell $26.0 million, principally due to working-capital movements. At March 31, 2014, current assets were $177.2 million and current liabilities $84.4 million. The company had $95.0 million of unused ABL revolver capacity. It reported compliance with debt covenants.
Material changes versus the prior comparable period
- Revenue declined 3.5%. OTC Healthcare revenue fell 4.3%, while Household Cleaning revenue increased 1.6%.
- Management attributed the revenue decline to a weak cough-and-cold season, increased competition (including the return of previously recalled competing products), the Phazyme divestiture, and gastrointestinal-brand declines. Care Pharma and new analgesic products partly offset these effects.
- Gross margin improved by 0.8 percentage points, mainly due to sourcing savings, lower promotional spending, and product mix.
- Operating cash flow decreased 18.9%; debt declined by $40.5 million year over year.
- The company issued $400 million of 5.375% notes due 2021, redeemed its $250 million 8.25% 2010 notes, and repaid approximately $120 million of term-loan principal. Year-end debt also included $250 million of 8.125% notes due 2020 and $287.5 million under the term loan.
- Care Pharma contributed to 2014 results from its July 2013 acquisition date; management said its pro forma effect on revenue and earnings was not material.
Outlook, risks, contingencies, and unusual items
- No numerical revenue or earnings guidance is provided. Management said it expects to finance operations over the next 12 months with operating cash flow and borrowings, and anticipated covenant compliance in fiscal 2015.
- After year-end, the company completed the Hydralyte acquisition on April 30, 2014, funded with cash and its credit facility. It also agreed to acquire Insight Pharmaceuticals for $750 million in cash, with closing expected in the first half of fiscal 2015, subject to customary conditions and antitrust clearance. Expected financing included cash, the ABL revolver, and an add-on term loan.
- Key risks include substantial leverage and restrictive covenants; customer concentration (Walmart was 19.5% of gross revenue and 24.1% of receivables); dependence on third-party manufacturers and a single primary U.S. distribution center; competition and private-label products; product recalls, litigation, and regulation; and possible impairment of goodwill and intangibles.
- Goodwill and intangible assets totaled $1.586 billion, about 88% of total assets. No impairment charge was recorded in 2014; certain household brands had experienced revenue declines, which could lead to future impairment.
- The $18.3 million debt-extinguishment loss related to premiums and write-offs from redeeming the 2010 notes. The filing also notes recent product recalls but gives no clear quantified aggregate financial effect.
- Auditors reported the financial statements fairly presented the company’s position under U.S. GAAP and concluded internal control over financial reporting was effective.
Important facts for investors to verify
- Confirm the issuer identity and reporting period: this filing is for Prestige Brands Holdings, Inc., fiscal year ended March 31, 2014.
- Track whether core OTC revenue declines persist, especially in cough-and-cold and gastrointestinal products, and whether Care Pharma and product launches offset them.
- Assess cash generation, working-capital needs, debt reduction, interest-rate exposure, and covenant headroom; a 1 percentage-point rate increase was estimated to reduce annual pretax earnings and cash flow by about $9.5 million.
- Verify the completion, financing, integration, and subsequent performance of Hydralyte and the proposed Insight acquisition, including added leverage.
- Monitor Walmart and other major-customer concentration, supply continuity, recall or litigation developments, and impairment sensitivity in the large intangible-asset balance.